Combination therapy of Anti-her3 antibodies
Patent Information
- Authority / Receiving Office
- US · United States
- Patent Type
- Applications(United States)
- Current Assignee / Owner
- F HOFFMANN LA ROCHE INC
- Publication Date
- 2016-06-09
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1 Figure 2 Figure 3
Abstract
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser. No. 14 / 151,626 filed on Jan. 9, 2014, now U.S. Pat. No. 9,180,185, which claims priority to European Patent Application No. EP 13151076.0 filed Jan. 11, 2013, the disclosures of both of which are incorporated herein by reference in their entirety.SEQUENCE LISTING
[0002] The present application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jan. 7, 2014, is named P5733US_ST25.txt and is 54,072 bytes in size.FIELD OF THE INVENTION
[0003] The present invention relates to the combination therapy of anti-HER3 antibodies with certain anti-HER antibodies.BACKGROUND OF THE INVENTION
[0004] Human HER3 (ErbB-3, ERBB3, c-erbB-3,c-erbB3, receptor tyrosine-protein kinase erbB-3, SEQ ID NO: 17) encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosi...